Abstract Number: 0907 • ACR Convergence 2020
Long-term Outcomes with Filgotinib, an Oral Selective Janus Kinase 1 Inhibitor: 100-week Data from an Open-label Extension (OLE) Study in Patients with Active Psoriatic Arthritis (PsA)
Background/Purpose: EQUATOR (NCT03101670) was a randomized, 16-week, Phase 2, multicenter, double-blind, placebo (PBO)‑controlled trial of filgotinib (FIL) in patients with active PsA ( Mease P,…Abstract Number: 1331 • ACR Convergence 2020
Carotid Ultrasound Findings in Psoriatic Arthritis: A Case-control Study
Background/Purpose: Patients with psoriatic arthritis (PsA) have an increased risk of cardiovascular disease (CVD). The carotid ultrasound, which measures both carotid intima-media thickness (cIMT) and…Abstract Number: 1361 • ACR Convergence 2020
Secukinumab Significantly Decreased Joint Synovitis Measured by Power Doppler Ultrasonography in Biologic-naïve Patients with Active Psoriatic Arthritis: Primary (12-Week) Results from a Randomized, Placebo-Controlled Phase III Study
Background/Purpose: Power Doppler (PD) ultrasonography (PDUS) is a sensitive non-invasive imaging technology used to assess joint synovitis and enthesitis of psoriatic arthritis (PsA) in clinical…Abstract Number: 1562 • ACR Convergence 2020
Subclinical Joint Inflammation of Hands by Magnetic Resonance Imaging in Patients with Psoriatic Arthritis in Clinical Remission Compared to Active Disease
Background/Purpose: Assessment of disease activity in psoriatic arthritis (PsA) is based on tender and swollen joint counts (TJC and SJC, respectively). Yet, the prevalence of…Abstract Number: 2026 • ACR Convergence 2020
Efficacy and Safety of Upadacitinib versus Placebo and Adalimumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Anti-Rheumatic Drugs: A Double-Blind, Randomized Controlled Phase 3 Trial
Background/Purpose: Upadacitinib (UPA), an oral, reversible, JAK inhibitor approved to treat rheumatoid arthritis (RA), is under evaluation for psoriatic arthritis (PsA). We assess efficacy and…Abstract Number: 0170 • ACR Convergence 2020
Utilizing Design Thinking to Develop a Decision Aid for Patients with Psoriasis and Psoriatic Arthritis
Background/Purpose: Given the complexity of available treatment recommendations, patients with psoriatic disease would benefit from a process fostering shared decision-making using a patient-centered approach. True…Abstract Number: 0319 • ACR Convergence 2020
Target Outcomes in Psoriatic Arthritis: Simultaneous Achievement of ACR50-Psoriasis Area and Severity Index 100 and Beyond: Insights from Open-Label, Assessor-Blinded Study at Week 24
Background/Purpose: Psoriatic Arthritis (PsA) treatment should aim to achieve robust improvement of arthritis as well as control of extra-articular manifestations like the skin. SPIRIT-H2H evaluated…Abstract Number: 0335 • ACR Convergence 2020
Interleukin-17 Blockade Leads to Shifts from Stage-based Towards Response-based Disease Clusters- Comparative Data from Very Early and Established Psoriatic Arthritis
Background/Purpose: Limited information exists about the very early forms of psoriatic arthritis (PsA). In particular, differences and responsiveness of patient-reported outcomes (PROs) in very early…Abstract Number: 0356 • ACR Convergence 2020
Bimekizumab Improves Patient-Reported Outcomes in Psoriatic Arthritis: 48-Week Results from a Phase 2b Study and Association Between Patient-Reported Outcomes and Disease Activity
Background/Purpose: Bimekizumab (BKZ), a humanized monoclonal IgG1 antibody that selectively neutralizes interleukin (IL)-17A and IL-17F, has shown clinical improvements in joint and skin outcomes and…Abstract Number: 0447 • ACR Convergence 2020
Magnetic Resonance Imaging Characteristics in Patients with Spondyloarthritis and Clinical Diagnosis of Heel Enthesitis: Screening Data from a Phase 3 Trial
Background/Purpose: Inflammation and pain at entheseal sites are the key clinical signs in patients (pts) with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA).1 Magnetic resonance…Abstract Number: 0875 • ACR Convergence 2020
Secukinumab Provides Sustained Improvements in Subgroup Analyses of Joint Tenderness and Swelling in Patients with Psoriatic Arthritis: 5‑Year Results from the Phase 3 FUTURE 2 Study
Background/Purpose: Secukinumab, a fully human monoclonal antibody that neutralizes interleukin‑17A, has shown long-term efficacy and tolerability in patients with psoriatic arthritis (PsA) in FUTURE 2.…Abstract Number: 0908 • ACR Convergence 2020
Guselkumab Efficacy in Adult Patients with Active Psoriatic Arthritis by Baseline Demographic and Disease Characteristics: Pooled Results of Two Phase 3, Randomized, Placebo-Controlled Studies
Background/Purpose: Guselkumab (GUS), a human monoclonal antibody targeting the IL-23p19-subunit, has shown consistent efficacy in psoriasis pts regardless of body weight/body mass index (BMI).1 GUS…Abstract Number: 1334 • ACR Convergence 2020
Does Interstitial Lung Disease Represent a Real Comorbidity in Spondyloarthritis Patients? Results from an Ultrasound, Monocentric, Pilot Study
Background/Purpose: Background: Interstitial lung disease (ILD) is a frequent complication in rheumatoid arthritis (RA) where it represents the most common extra-articular involvement (with a prevalence…Abstract Number: 1363 • ACR Convergence 2020
Efficacy of Secukinumab on Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Post Hoc Analysis from a Phase 3 Trial
Background/Purpose: The phase 3 randomized controlled trial FUTURE 5 (NCT02404350) showed the efficacy of secukinumab (SEC) improving clinical signs, symptoms, and radiographic progression in patients…Abstract Number: 1564 • ACR Convergence 2020
Feasibility of Ultra-low-dose, Short-duration, Total-body Evaluation of Inflammatory Arthritis Using uEXPLORER 18F-FDG PET/CT
Background/Purpose: The uEXPLORER system enables the unique, simultaneous acquisition of PET data over the entire adult human body with a high-sensitivity, alongside concurrent CT data.…
- « Previous Page
- 1
- …
- 44
- 45
- 46
- 47
- 48
- …
- 81
- Next Page »